secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001104659-26-020070
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q4 net loss $19.8M; cash $151.4M; ATI-052 POC trials underway
---------------------------------------------------------------------

- Net loss of $19.8M in Q4 2025 vs $96.6M in Q4 2024; full year net loss $64.9M vs $132.1M.
- Total revenue $1.3M in Q4 2025 vs $9.2M prior year; decrease due to 2024 Lilly milestone.
- Cash, equivalents and marketable securities $151.4M as of Dec 31, 2025; cash runway into H2 2028.
- Interim Phase 1a data for anti-TSLP/IL-4Rα bispecific ATI-052 support rapid advancement; Phase 1b POC trials in AD and asthma initiated.
- IND filing for lead ITK inhibitor ATI-9494 expected H2 2026; ATI-2138 showed hair regrowth in alopecia model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926020070/0001104659-26-020070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926020070/acrs-20260226x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-020070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer